|
Muscular Dystrophy
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
No pathogenic MG53 mutations were identified in 50 muscular dystrophy patients, suggesting that MG53 is unlikely to be a common cause of muscular dystrophy in Australia.
|
21412170 |
2011 |
|
Muscular Dystrophy
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
Membrane repair defects in muscular dystrophy are linked to altered interaction between MG53, caveolin-3, and dysferlin.
|
19380584 |
2009 |
|
Muscular Dystrophy
|
0.050 |
Biomarker
|
disease |
BEFREE |
There is great potential for the use of recombinant human MG53 in treating muscular dystrophy and other diseases in which compromised membrane integrity contributes to the disease.
|
23699904 |
2013 |
|
Muscular Dystrophy
|
0.050 |
Biomarker
|
disease |
BEFREE |
Our recent studies show that MG53 is essential for muscle membrane repair, and defects in MG53 function are linked to muscular dystrophy and cardiac dysfunction.
|
21343302 |
2011 |
|
Metabolic Diseases
|
0.030 |
Biomarker
|
group |
BEFREE |
We will focus on the pathways that MG53 regulates and how the dysregulation of MG53 leads to metabolic disorders, thereby establishing a causal relationship between sustained upregulation of MG53 and the development of muscle insulin resistance and metabolic disorders.
|
29017896 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.020 |
Biomarker
|
disease |
BEFREE |
Furthermore, the potential involvement of circulating MG53 in the pathogenesis of T2DM was assessed by neutralizing blood MG53 with monoclonal antibodies in diabetic db/db mice.
|
30586741 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.020 |
Biomarker
|
disease |
BEFREE |
These results indicated that MSC infusion has therapeutic effects in rats and that MG53 in skeletal muscle may be a promising novel therapeutic target protein for MSC‑mediated amelioration of insulin resistance in T2D.
|
29693163 |
2018 |
|
Heart failure
|
0.020 |
Biomarker
|
disease |
BEFREE |
Enhancing muscle membrane repair by gene delivery of MG53 ameliorates muscular dystrophy and heart failure in δ-Sarcoglycan-deficient hamsters.
|
22314291 |
2012 |
|
Heart failure
|
0.020 |
Biomarker
|
disease |
BEFREE |
Herein, we will review the link between structural and molecular remodelling of the sarcolemma associated with the progression of HF, specifically considering the evidence for: (i) Whether intrinsic, evolutionary conserved, plasma membrane injury-repair mechanisms are in operation in the heart, and (ii) if deficits in key 'wound-healing' proteins (annexins, dysferlin, EHD2 and MG53) may play a yet to be fully appreciated role in triggering sarcolemma microdomain remodelling and/or necrosis.
|
31520263 |
2019 |
|
Congestive heart failure
|
0.020 |
Biomarker
|
disease |
BEFREE |
Herein, we will review the link between structural and molecular remodelling of the sarcolemma associated with the progression of HF, specifically considering the evidence for: (i) Whether intrinsic, evolutionary conserved, plasma membrane injury-repair mechanisms are in operation in the heart, and (ii) if deficits in key 'wound-healing' proteins (annexins, dysferlin, EHD2 and MG53) may play a yet to be fully appreciated role in triggering sarcolemma microdomain remodelling and/or necrosis.
|
31520263 |
2019 |
|
Myopathy
|
0.020 |
Biomarker
|
group |
BEFREE |
Upon cell-surface lesion MG53 recruits the vesicles to the repair site in an oxidation-dependent manner and MG53-knockout mice develop progressive myopathy associated with defective membrane repair.
|
19202355 |
2009 |
|
Myopathy
|
0.020 |
Biomarker
|
group |
BEFREE |
This study explored the expression and localization of MG53 in human skeletal muscle, how membrane repair proteins are modulated in various forms of muscular dystrophy, and whether MG53 is a primary cause of human muscle disease.
|
21412170 |
2011 |
|
Metabolic Syndrome X
|
0.020 |
Biomarker
|
disease |
BEFREE |
TRIM72 is involved in insulin resistance and metabolic syndrome, which are risk factors of colon cancer.
|
29806630 |
2018 |
|
Metabolic Syndrome X
|
0.020 |
Biomarker
|
disease |
BEFREE |
Using perfused rodent hearts or skeletal muscle, we investigated whether high glucose, high insulin, or their combination (conditions mimicking metabolic syndrome or T2DM) alters MG53 protein concentration in the perfusate.
|
30586741 |
2019 |
|
Colorectal Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
TRIM72 Immunohistochemical Expression Can Predict Relapse in Colorectal Carcinoma.
|
30852740 |
2019 |
|
Diabetes Mellitus
|
0.010 |
Biomarker
|
group |
BEFREE |
Second, hyperglycemia is accompanied by increased circulating MG53 in humans and rodents with diabetes mellitus.
|
30586741 |
2019 |
|
Muscular Dystrophy, Duchenne
|
0.010 |
Biomarker
|
disease |
BEFREE |
MG53 has been implicated in cardiac ischaemia-reperfusion injury, and serum MG53 provides a biomarker of skeletal muscle injury in the mdx mouse model of Duchenne muscular dystrophy.
|
26790476 |
2016 |
|
Heart valve disease
|
0.010 |
Biomarker
|
group |
BEFREE |
Conclusions Together, our data characterize valve interstitial cell membrane repair as a novel mechanism of protection against valvular remodeling and assess potential in vivo roles of MG 53 in preventing valvular heart disease.
|
30741589 |
2019 |
|
Hyperinsulinism
|
0.010 |
Biomarker
|
disease |
BEFREE |
First, high glucose or high insulin induces MG53 secretion from isolated rodent hearts and skeletal muscle.
|
30586741 |
2019 |
|
Lung diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Our data indicate a physiological function for MG53 in the lung and suggest that targeting membrane repair may be an effective means for treatment or prevention of lung diseases.
|
25034454 |
2014 |
|
Ventricular arrhythmia
|
0.010 |
Biomarker
|
disease |
BEFREE |
MG53 knockout enhances I<sub>to,f</sub> remodeling and action potential duration prolongation and increases susceptibility to ventricular arrhythmia in mouse cardiac hypertrophy.
|
30760025 |
2019 |
|
Malignant neoplasm of tongue
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here, the role of MG53 in the tumorigenesis of tongue cancer is analyzed in vitro and in vivo.
|
30690890 |
2019 |
|
Memory impairment
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
In addition, MG53 ameliorated LPS-induced memory impairment and neuronal cell death in mice.
|
31260721 |
2019 |
|
Sore to touch
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Among the unusual proteins, Four and a half LIM domains 1 (FHL1) and Tripartite motif protein 72 (TRIM72) correlated respectively negatively and positively with beef tenderness.
|
29412918 |
2018 |
|
Forgetful
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
In addition, MG53 ameliorated LPS-induced memory impairment and neuronal cell death in mice.
|
31260721 |
2019 |